References
- Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181–192. doi:https://doi.org/10.1038/s41579-018-0118-9.
- He G, Sun Z, Zhao Y, et al. Zhou Q: β-coronavirus infectious diseases: recommended strategies for the prevention and control of transmission. Int J Clin Exp Pathol. 2020;13:1060–1065.
- Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi:https://doi.org/10.1038/s41586-020-2012-7.
- Astuti IY. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes Metab Syndr. 2020;14:407–412. doi:https://doi.org/10.1016/j.dsx.2020.04.020.
- Kim D, Lee JY, Yang JS, et al. The architecture of SARS-CoV-2 transcriptome. Cell. 2020;181:914–921, e910. doi:https://doi.org/10.1016/j.cell.2020.04.011.
- Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5:237. doi:https://doi.org/10.1038/s41392-020-00352-y.
- Funk CD, Laferrière C, Ardakani A. A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic. Front Pharmacol. 2020;11(937):1–17.
- Callaway E. The coronavirus is mutating – does it matter?Nature. 2020;585:174–177. doi:https://doi.org/10.1038/d41586-020-02544-6.
- Vilar S, Isom DG. One year of SARS-CoV-2: how much has the virus changed?
- Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020–January 12, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:95–99. doi:https://doi.org/10.15585/mmwr.mm7003e2.
- O’Driscoll M, Ribeiro Dos SG, Wang L, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2020 ;590(7844):140–145.
- Chen Y, Klein SL, Garibaldi BT, et al. Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res Rev. 2021;65:101205. doi:https://doi.org/10.1016/j.arr.2020.101205.
- Del Giudice G, Goronzy JJ, Grubeck-Loebenstein B, et al. Fighting against a protean enemy: immunosenescence, vaccines, and healthy aging. NPJ Aging Mech Dis. 2017;4:1. doi:https://doi.org/10.1038/s41514-017-0020-0.
- Gibson KL, Wu YC, Barnett Y, et al. B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell. 2009;8:18–25. doi:https://doi.org/10.1111/j.1474-9726.2008.00443.x.
- Haq K, McElhaney JE. Immunosenescence: Influenza vaccination and the elderly. Curr Opin Immunol. 2014;29:38–42. doi:https://doi.org/10.1016/j.coi.2014.03.008.
- Weng NP. Aging of the immune system: how much can the adaptive immune system adapt?Immunity. 2006;24:495–499. doi:https://doi.org/10.1016/j.immuni.2006.05.001.
- Nikolich-Žugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol. 2018;19(1):10–19. doi:https://doi.org/10.1038/s41590-018-0205-0.
- Cambier J. Immunosenescence: a problem of lymphopoiesis, homeostasis, microenvironment, and signaling. Immunol Rev. 2005;205:5–6. doi:https://doi.org/10.1111/j.0105-2896.2005.00276.x.
- Campisi J. Cellular senescence and lung function during aging, Yin and Yang. Ann Am Thorac Soc. 2016;13 Suppl 5:S402–S406. doi:https://doi.org/10.1513/AnnalsATS.201609-703AW.
- Murray MA, Chotirmall SH. The impact of immunosenescence on pulmonary disease. Mediators Inflamm. 2015;2015:692546. doi:https://doi.org/10.1155/2015/692546.
- Rea IM, Gibson DS, McGilligan V, et al. Age and age-related diseases: role of inflammation triggers and cytokines. Front Immunol. 2018;9(586):1–28.
- Wong CK, Smith CA, Sakamoto K, et al. Aging impairs alveolar macrophage phagocytosis and increases influenza-induced mortality in mice. J Immunol. 2017;199:1060–1068. doi:https://doi.org/10.4049/jimmunol.1700397.
- van Beek AA, Van den Bossche J, Mastroberardino PG, et al. Metabolic alterations in aging macrophages: ingredients for inflammaging?Trends Immunol. 2019;40:113–127. doi:https://doi.org/10.1016/j.it.2018.12.007.
- Nainu F, Shiratsuchi A, Nakanishi Y. Induction of apoptosis and subsequent phagocytosis of virus-infected cells as an antiviral mechanism. Front Immunol. 2017;8(1220):1–11.
- Fujimoto I, Pan J, Takizawa T, et al. Virus clearance through apoptosis-dependent phagocytosis of influenza A virus-infected cells by macrophages. J Virol. 2000;74:3399–3403. doi:https://doi.org/10.1128/jvi.74.7.3399-3403.2000.
- Puttur F, Gregory LG, Lloyd CM. Airway macrophages as the guardians of tissue repair in the lung. Immunol Cell Biol. 2019;97:246–257. doi:https://doi.org/10.1111/imcb.12235.
- Snelgrove RJ, Goulding J, Didierlaurent AM, et al. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol. 2008;9:1074–1083. doi:https://doi.org/10.1038/ni.1637.
- Yu X, Buttgereit A, Lelios I, et al. The cytokine TGF-β promotes the development and homeostasis of alveolar macrophages. Immunity. 2017;47:903–912.e904. doi:https://doi.org/10.1016/j.immuni.2017.10.007.
- Kulikauskaite J, Wack A. Teaching old dogs new tricks? The plasticity of lung alveolar macrophage subsets. Trends Immunol. 2020;41:864–877. doi:https://doi.org/10.1016/j.it.2020.08.008.
- Hussell T, Bell TJ. Alveolar macrophages: plasticity in a tissue-specific context. Nat Rev Immunol. 2014;14:81–93. doi:https://doi.org/10.1038/nri3600.
- Wenisch C, Patruta S, Daxböck F, et al. Effect of age on human neutrophil function. J Leukoc Biol. 2000;67(1):40–45. doi:https://doi.org/10.1002/jlb.67.1.40.
- Ortmann W, Kolaczkowska E. Age is the work of art? Impact of neutrophil and organism age on neutrophil extracellular trap formation. Cell Tissue Res. 2018;371:473–488. doi:https://doi.org/10.1007/s00441-017-2751-4.
- Xu F, Zhang C, Zou Z, et al. Aging-related Atg5 defect impairs neutrophil extracellular traps formation. Immunology. 2017;151:417–432. doi:https://doi.org/10.1111/imm.12740.
- Ruddle NH, Akirav EM. Secondary lymphoid organs: responding to genetic and environmental cues in ontogeny and the immune response. J Immunol. 2009;183:2205–2212. doi:https://doi.org/10.4049/jimmunol.0804324.
- Goronzy JJ, Fang F, Cavanagh MM, et al. Naive T cell maintenance and function in human aging. J Immunol. 2015;194:4073–4080. doi:https://doi.org/10.4049/jimmunol.1500046.
- Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4+ T cells in immunity to viruses. Nat Rev Immunol. 2012;12:136–148. doi:https://doi.org/10.1038/nri3152.
- Palmer S, Albergante L, Blackburn CC, et al. Thymic involution and rising disease incidence with age. Proc Natl Acad Sci USA. 2018;115:1883–1888. doi:https://doi.org/10.1073/pnas.1714478115.
- Turner VM, Mabbott NA. Influence of ageing on the microarchitecture of the spleen and lymph nodes. Biogerontology. 2017;18:723–738. doi:https://doi.org/10.1007/s10522-017-9707-7.
- Dunn-Walters DK. The ageing human B cell repertoire: a failure of selection?Clin Exp Immunol. 2016;183:50–56. doi:https://doi.org/10.1111/cei.12700.
- Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27:28–33. doi:https://doi.org/10.1038/s41591-020-01202-8.
- Vellas C, Delobel P, de Souto Barreto P, et al. COVID-19, virology and geroscience: a perspective. J Nutr Health Aging. 2020;24:685–691. doi:https://doi.org/10.1007/s12603-020-1416-2.
- Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. doi:https://doi.org/10.1016/j.ebiom.2020.102763.
- Laing AG, Lorenc A, Del Molino Del Barrio I, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020;26:1623–1635. doi:https://doi.org/10.1038/s41591-020-1038-6.
- Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71:762–768. doi:https://doi.org/10.1093/cid/ciaa248.
- Biswas A, Bhattacharjee U, Chakrabarti AK, et al. Emergence of novel coronavirus and COVID-19: whether to stay or die out?Crit Rev Microbiol. 2020;46:182–193. doi:https://doi.org/10.1080/1040841X.2020.1739001.
- Zhang YY, Li BR, Ning BT. The comparative immunological characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 coronavirus infections. Front Immunol. 2020;11:2033. doi:https://doi.org/10.3389/fimmu.2020.02033.
- Li S, Jiang L, Li X, et al. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight. 2020;5(12):5. doi:https://doi.org/10.1172/jci.insight.138070.
- Peng Y, Mentzer AJ, Liu G, et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol. 2020;21:1336–1345. doi:https://doi.org/10.1038/s41590-020-0782-6.
- Johnstone J, Parsons R, Botelho F, et al. Immune biomarkers predictive of respiratory viral infection in elderly nursing home residents. PLoS One. 2014;9:e108481. doi:https://doi.org/10.1371/journal.pone.0108481.
- Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34:327–331. doi:https://doi.org/10.23812/CONTI-E.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi:https://doi.org/10.1016/S0140-6736(20)30183-5.
- Ciulla MM. SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs. Hypertens Res. 2020;43:985–986. doi:https://doi.org/10.1038/s41440-020-0488-z.
- Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol. 2020;92:726–730. doi:https://doi.org/10.1002/jmv.25785.
- Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020:5(48):eabc8413.
- Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020;11:827. doi:https://doi.org/10.3389/fimmu.2020.00827.
- Wang Z, Wan Y, Qiu C, et al. Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8+ T cells. Nat Commun. 2015;6:6833. doi:https://doi.org/10.1038/ncomms7833.
- Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489–1501. e1415. doi:https://doi.org/10.1016/j.cell.2020.05.015.
- Patel A, Walters J, Reuschel EL, et al. Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model. bioRxiv. 2020. bioRxiv. doi:https://doi.org/10.1101/2020.07.28.225649.
- Tebas P, Yang S, Boyer JD, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClin Med. 2021;31:100689. doi:https://doi.org/10.1016/j.eclinm.2020.100689.
- Wu A, Peng Y, Huang B, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27:325–328. doi:https://doi.org/10.1016/j.chom.2020.02.001.
- Zhang C, Maruggi G, Shan H, et al. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019;10(594);1–13.
- Kowalski PS, Rudra A, Miao L, et al. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27:710–728. doi:https://doi.org/10.1016/j.ymthe.2019.02.012.
- Reichmuth AM, Oberli MA, Jaklenec A, et al. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7:319–334. doi:https://doi.org/10.4155/tde-2016-0006.
- Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2020;28(3-4):117–129.
- Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383:2427–2438. doi:https://doi.org/10.1056/NEJMoa2028436.
- Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586:567–571. doi:https://doi.org/10.1038/s41586-020-2622-0.
- Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020;383(16):1544–1555. doi:https://doi.org/10.1056/NEJMoa2024671.
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:https://doi.org/10.1056/NEJMoa2035389.
- Walsh EE, Frenck RW Jr., Falsey AR, et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med. 2020;383:2439–2450. doi:https://doi.org/10.1056/NEJMoa2027906.
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615. doi:https://doi.org/10.1056/NEJMoa2034577.
- Torjesen I. Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination. BMJ. 2021;372:n149. doi:https://doi.org/10.1136/bmj.n149.
- Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383:2320–2332. doi:https://doi.org/10.1056/NEJMoa2026920.
- Todorov G, Uversky VN. A possible path towards rapid development of live-attenuated SARS-CoV-2 vaccines: plunging into the natural pool. Biomolecules. 2020;10(10):1438. doi:https://doi.org/10.3390/biom10101438.
- https://www.pharmaceutical-technology.com/news/codagenix-sii-dosing-vaccine/.
- Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–478. doi:https://doi.org/10.1016/S0140-6736(20)31604-4.
- Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi:https://doi.org/10.1016/S0140-6736(20)32661-1.
- Barrett JR, Belij-Rammerstorfer S, Dold C, et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021;27(2):279–288. doi:https://doi.org/10.1038/s41591-020-01179-4.
- Graham F. Daily briefing: Oxford–AstraZeneca COVID vaccine is back on track. Nature. 2021.
- Sattler A, Angermair S, Stockmann H, et al. SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition. J Clin Invest. 2020;130:6477–6489. doi:https://doi.org/10.1172/JCI140965.
- de Candia P, Prattichizzo F, Garavelli S, et al. T cells: warriors of SARS-CoV-2 infection. Trends Immunol. 2021;42:18–30. doi:https://doi.org/10.1016/j.it.2020.11.002.
- Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158–168. doi:https://doi.org/10.1016/j.cell.2020.08.017.
- Saule P, Trauet J, Dutriez V, et al. Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment. Mech Ageing Dev. 2006;127:274–281. doi:https://doi.org/10.1016/j.mad.2005.11.001.
- El Shikh ME, El Sayed RM, Sukumar S, et al. Activation of B cells by antigens on follicular dendritic cells. Trends Immunol. 2010;31:205–211. doi:https://doi.org/10.1016/j.it.2010.03.002.
- Lelic A, Verschoor CP, Ventresca M, et al. The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age. PLoS Pathog. 2012;8(12):e1003076. doi:https://doi.org/10.1371/journal.ppat.1003076.
- Izurieta HS, Wernecke M, Kelman J, et al. Effectiveness and duration of protection provided by the live-attenuated Herpes Zoster Vaccine in the Medicare population ages 65 years and older. Clin Infect Dis. 2017;64:785–793. doi:https://doi.org/10.1093/cid/ciw854.
- Calabro S, Tritto E, Pezzotti A, et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine. 2013;31:3363–3369. doi:https://doi.org/10.1016/j.vaccine.2013.05.007.
- Del Giudice G, Rappuoli R. Inactivated and adjuvanted influenza vaccines. Curr Top Microbiol Immunol. 2015;386:151–180. doi:https://doi.org/10.1007/82_2014_406.
- Magnusson SE, Reimer JM, Karlsson KH, et al. Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine. 2013;31:1725–1733. doi:https://doi.org/10.1016/j.vaccine.2013.01.039.
- De Serres G, Gariépy MC, et al. Short and long-term safety of the 2009 AS03-adjuvanted pandemic vaccine. PLoS One. 2012;7(7):e38563. doi:https://doi.org/10.1371/journal.pone.0038563.
- Chen WH, Jackson LA, Edwards KM, et al. Persistence of antibody to Influenza A/H5N1 vaccine virus: impact of AS03 adjuvant. Clin Vaccine Immunol. 2016;23:73–77. doi:https://doi.org/10.1128/CVI.00475-15.
- Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–2096. doi:https://doi.org/10.1056/NEJMoa1501184.
- Moser C, Amacker M, Zurbriggen R. Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev Vaccines. 2011;10:437–446. doi:https://doi.org/10.1586/erv.11.15.
- Conne P, Gauthey L, Vernet P, et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine. 1997;15(15):1675–1679. doi:https://doi.org/10.1016/S0264-410X(97)00087-X.
- Glück R, Mischler R, Finkel B, et al. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet. 1994;344:160–163. doi:https://doi.org/10.1016/S0140-6736(94)92758-8.
- Saade F, Honda-Okubo Y, Trec S, et al. A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine. 2013;31:1999–2007. doi:https://doi.org/10.1016/j.vaccine.2012.12.077.
- Honda-Okubo Y, Saade F, Petrovsky N. Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine. 2012;30:5373–5381. doi:https://doi.org/10.1016/j.vaccine.2012.06.021.
- Dolter KE, Evans CF, Ellefsen B, et al. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation. Vaccine. 2011;29:795–803. doi:https://doi.org/10.1016/j.vaccine.2010.11.011.
- Reimer JM, Karlsson KH, Lövgren-Bengtsson K, et al. Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS One. 2012;7:e41451. doi:https://doi.org/10.1371/journal.pone.0041451.
- Bengtsson KL, Karlsson KH, Magnusson SE, et al. Matrix-M adjuvant: enhancing immune responses by ‘setting the stage’ for the antigen. Expert Rev Vaccines. 2013;12:821–823. doi:https://doi.org/10.1586/14760584.2013.814822.
- Antrobus RD, Lillie PJ, Berthoud TK, et al. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP + M1 in adults aged over 50 years. PLoS One. 2012;7:e48322. doi:https://doi.org/10.1371/journal.pone.0048322.
- Altenburg AF, Kreijtz JH, de Vries RD, et al. Modified vaccinia virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses. 2014;6:2735–2761. doi:https://doi.org/10.3390/v6072735.
- Jordan E, Lawrence SJ, Meyer TPH, et al. Broad antibody and cellular immune response from a phase 2 clinical trial with a novel multivalent poxvirus-based respiratory syncytial virus vaccine. J Infect Dis. 2021;223:1062–1072. doi:https://doi.org/10.1093/infdis/jiaa460.
- Suzuki M, Dhoubhadel BG, Ishifuji T, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017;17:313–321. doi:https://doi.org/10.1016/S1473-3099(17)30049-X.
- van Deursen AMM, van Houten MA, Webber C, et al. Immunogenicity of the 13-valent pneumococcal conjugate vaccine in older adults with and without comorbidities in the community-acquired pneumonia immunization trial in adults (CAPiTA). Clin Infect Dis. 2017;65:787–795. doi:https://doi.org/10.1093/cid/cix419.
- Nived P, Jönsson G, Settergren B, et al. Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients. Arthritis Res Ther. 2020;22(1):36. doi:https://doi.org/10.1186/s13075-020-02256-2.
- Weyand CM, Goronzy JJ. Aging of the immune system. Mechanisms and therapeutic targets. Ann Am Thorac Soc. 2016;13 Suppl 5:S422–S428. doi:https://doi.org/10.1513/AnnalsATS.201602-095AW.
- Crooke SN, Ovsyannikova IG, Poland GA, et al. Immunosenescence and human vaccine immune responses. Immun Ageing. 2019;16:25. doi:https://doi.org/10.1186/s12979-019-0164-9.
- Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21:73–82. doi:https://doi.org/10.1038/s41577-020-00480-0.
- Cai Y, Zhang J, Xiao T, et al. Distinct conformational states of SARS-CoV-2 spike protein. Science. 2020;369:1586–1592. doi:https://doi.org/10.1126/science.abd4251.
- Huang Y, Yang C, Xu XF, et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41:1141–1149. doi:https://doi.org/10.1038/s41401-020-0485-4.
- Wang D, Mai J, Zhou W, et al. Immunoinformatic analysis of T- and B-cell epitopes for SARS-CoV-2 vaccine design. Vaccines (Basel). 2020;8(3):355. doi:https://doi.org/10.3390/vaccines8030355.
- Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584:120–124. doi:https://doi.org/10.1038/s41586-020-2381-y.
- Piccoli L, Park YJ, Tortorici MA, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183(4):1024–1042. doi:https://doi.org/10.1016/j.cell.2020.09.037.
- Dearlove B, Lewitus E, Bai H, et al. A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. Proc Natl Acad Sci USA. 2020;117:23652–23662. doi:https://doi.org/10.1073/pnas.2008281117.
- Laha S, Chakraborty J, Das S, et al. Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission. Infect Genet Evol. 2020;85:104445.
- Pokhrel S, Kraemer BR, Mochly-Rosen D. Natural variants in SARS-CoV-2 S protein pinpoint structural and functional hotspots; implications for prophylaxis strategies. 2021.
- Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182:1284–1294,e1289. doi:https://doi.org/10.1016/j.cell.2020.07.012.
- Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020;9:9. doi:https://doi.org/10.7554/eLife.61312.
- Fratev F. The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: a free energy of perturbation study. 2020. bioRxiv. doi:https://doi.org/10.1101/2020.12.23.424283.
- Xie X, Zou J, Fontes-Garfias CR, et al. Neutralization of SARS-CoV-2 spike69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nature Medicine 2021;27:620–621.
- Krammer F, Pica N, Hai R, et al. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol. 2013;87:6542–6550. doi:https://doi.org/10.1128/JVI.00641-13.
- Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184:476–488,e411. doi:https://doi.org/10.1016/j.cell.2020.12.015.
- Georgieva M, Buckee CO, Lipsitch M. Models of immune selection for multi-locus antigenic diversity of pathogens. Nat Rev Immunol. 2019;19:55–62. doi:https://doi.org/10.1038/s41577-018-0092-5.
- Krammer F, Pica N, Hai R, Tan GS, et al. Hemagglutinin stalk-reactive antibodies are boosted following sequential infection with seasonal and pandemic H1N1 Influenza Virus in mice. J Virol. 2012;86:10302–10307. doi:https://doi.org/10.1128/JVI.01336-12.
- Nachbagauer R, Feser J, Naficy A, et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat Med. 2021;27:106–114. doi:https://doi.org/10.1038/s41591-020-1118-7.
- Biswas A, Chakrabarti AK, Dutta S. Current challenges: from the path of "original antigenic sin" towards the development of universal flu vaccines. Int Rev Immunol. 2020;39:21–36. doi:https://doi.org/10.1080/08830185.2019.1685990.
- Xiong X, Qu K, Ciazynska KA, et al. A thermostable, closed SARS-CoV-2 spike protein trimer. Nat Struct Mol Biol. 2020;27:934–941. doi:https://doi.org/10.1038/s41594-020-0478-5.
- Mortola E, Roy P. Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. FEBS Lett. 2004;576:174–178. doi:https://doi.org/10.1016/j.febslet.2004.09.009.
- Liu YV, Massare MJ, Barnard DL, et al. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine. 2011;29(38):6606–6613. doi:https://doi.org/10.1016/j.vaccine.2011.06.111.
- Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197:825–835. doi:https://doi.org/10.1086/528696.
- Levin MJ, Schmader KE, Pang L, et al. Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults. J Infect Dis. 2016;213:14–22. doi:https://doi.org/10.1093/infdis/jiv480.
- Jefferson T, Rivetti D, Rivetti A, et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005;366:1165–1174. doi:https://doi.org/10.1016/S0140-6736(05)67339-4.
- Ciabattini A, Nardini C, Santoro F, et al. Vaccination in the elderly: the challenge of immune changes with aging. Semin Immunol. 2018;40:83–94. doi:https://doi.org/10.1016/j.smim.2018.10.010.
- Nicholson KG, Abrams KR, Batham S, et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis. 2011;11:91–101. doi:https://doi.org/10.1016/S1473-3099(10)70296-6.
- Herzog C, Hartmann K, Künzi V, et al. Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine. 2009;27:4381–4387. doi:https://doi.org/10.1016/j.vaccine.2009.05.029.
- Joines RW, Blatter M, Abraham B, et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine. 2001;19(32):4710–4719. doi:https://doi.org/10.1016/S0264-410X(01)00240-7.
- Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs. 2003;63:1021–1051. doi:https://doi.org/10.2165/00003495-200363100-00006.
- https://clinicaltrials.gov/ct2/show/NCT03026348.
- Langley JM, MacDonald LD, Weir GM, et al. A respiratory syncytial virus vaccine based on the small hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study. J Infect Dis. 2018;218:378–387. doi:https://doi.org/10.1093/infdis/jiy177.